Metreleptin
- Generic Name
- Metreleptin
- Brand Names
- Myalept, Myalepta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 186018-45-1
- Unique Ingredient Identifier
- TL60C27RLH
- Background
Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with congenital or acquired lipodystrophy. Affecting less than 500 people worldwide, lipodystrophy is characterized by a lack of adipose tissue, fat deposition in the muscles and liver, and metabolic complications such a...
- Indication
Metreleptin is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
- Associated Conditions
- Congenital leptin deficiency
- Associated Therapies
- -
MEASuRE: Metreleptin Effectiveness And Safety Registry
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02325674
- Locations
- 🇫🇷
Hôpital Robert Debré, Paris, Paris, France, France
🇺🇸University Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸City of Hope, Duarte, California, United States
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
- Conditions
- Interventions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2024-11-26
- Target Recruit Count
- 30
- Registration Number
- NCT02262806
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 30
- Registration Number
- NCT02262832
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
- Conditions
- Interventions
- First Posted Date
- 2012-09-05
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 23
- Registration Number
- NCT01679197
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
- First Posted Date
- 2008-05-14
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 41
- Registration Number
- NCT00677313
- Locations
- 🇺🇸
Research Site, Greenville, North Carolina, United States
🇺🇸Local Institution, Reno, Nevada, United States
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
- Conditions
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 636
- Registration Number
- NCT00673387
- Locations
- 🇺🇸
Research Site, Olympia, Washington, United States
Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Elif Oral
- Target Recruit Count
- 9
- Registration Number
- NCT00596934
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 177
- Registration Number
- NCT00392925
- Locations
- 🇺🇸
Research Site, Olympia, Washington, United States
Role of Leptin in the Neuroendocrine and Immune Response to Fasting
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 13
- Registration Number
- NCT00140231
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT00140244
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.